Bluejay Diagnostics (NASDAQ:BJDX) Posts Earnings Results

Bluejay Diagnostics (NASDAQ:BJDX) released its earnings results on Friday. The company reported ($1.01) EPS for the quarter, Zacks reports.

Bluejay Diagnostics Stock Down 1.3%

Shares of NASDAQ:BJDX traded down $0.02 on Friday, reaching $1.57. 144,439 shares of the company’s stock were exchanged, compared to its average volume of 301,088. The business’s 50-day moving average is $1.93 and its two-hundred day moving average is $1.74. Bluejay Diagnostics has a fifty-two week low of $1.26 and a fifty-two week high of $10.20. The firm has a market capitalization of $2.84 million, a price-to-earnings ratio of -0.01 and a beta of 0.60.

Analyst Upgrades and Downgrades

BJDX has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of Bluejay Diagnostics to a “sell” rating in a research note on Saturday, November 1st. Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Wednesday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.